Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$81.16 USD

81.16
7,966,400

+0.27 (0.33%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed at $64.86 in the latest trading session, marking a -0.51% move from the prior day.

Will High Medical Costs Affect UnitedHealth (UNH) Q2 Earnings?

UnitedHealth's (UNH) second-quarter results are likely to reflect growth in memberships and expense levels.

Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study

Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Zacks Analyst Blog Highlights BHP Group, AstraZeneca, The Boeing, Diageo and General Mills

BHP Group, AstraZeneca, The Boeing, Diageo and General Mills are part of the Zacks top Analyst Blog.

Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

Astrazeneca (AZN) closed at $64.85 in the latest trading session, marking a -0.86% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for BHP Group, AstraZeneca & Boeing

Today's Research Daily features new research reports on 16 major stocks, including BHP Group Limited (BHP), AstraZeneca PLC (AZN) and The Boeing Company (BA).

Here's Why Astrazeneca (AZN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine

Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed at $71.67 in the latest trading session, marking a -0.08% move from the prior day.

Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $71.73, moving -0.54% from the previous trading session.

Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate

Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.

FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer

Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.

Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $73.95, marking a -1.69% move from the previous day.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

Astrazeneca (AZN) Gains But Lags Market: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $74.13, moving +0.38% from the previous trading session.

AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review

The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $73.85, moving -0.28% from the previous trading session.

AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies

AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag

Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.

GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults

The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.